Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zhijun Pharmaceutical To Bring Korean Gastric Drug Into China

This article was originally published in PharmAsia News

Executive Summary

Yuhan Corp., the first pharmaceutical company to list in Korea, recently granted Shenzhen Zhijun Pharmaceutical exclusive rights to make and sell its patented gastritis drug Revanex. The licensing agreement marks the strengthening collaboration between China and Korea in conducting R&D. The world's only potassium-competitive acid blocker and new-generation reversible proton pump inhibitor, Revanex has applied for patents in Europe, the U.S., Japan, Korea, China and India. Yuhan was the first Korean drug firm to receive Korea's GMP and GLP authentication and the U.S. cGMP authentication. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts